The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( ($HK:1276) ). Jiangsu Hengrui Pharmaceuticals Co., Ltd.
The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has granted ...
Citing that there is a concern of the risk of genital mycosis and urinary tract infection (UTI) with Empagliflozin, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback